Literature DB >> 22898483

A new perspective to determine the severity of cases with Crimean-Congo hemorrhagic fever.

Mehmet Bakir1, Aynur Engin, Mustafa Gokhan Gozel, Nazif Elaldi, Saadettin Kilickap, Ziynet Cinar.   

Abstract

BACKGROUND &
OBJECTIVES: We have established a severity grading score (SGS) system for predicting the fatality in Crimean - Congo hemorrhagic fever (CCHF) for the first time.
METHODS: This SGS has been set up by using several variables which were assumed to be associated with mortality according to the literature and also were considered to have clinical importance.
RESULTS: In all, 237 patients who had symptoms of CCHF for <5 days were included. The patients were grouped into three categories according to the mortality risk by using SGS as follows : low or no risk, intermediate and high risk groups. A SGS <5 showed no association with mortality (there were 158 cases in this group and all survived). This group constituted 66.7% of all the patients with CCHF. A SGS 6-10 showed moderate risk of mortality (10%) and seven out of 70 patients in this group died. SGS >11 means high risk for mortality (67%) and six out of 9 patients in this group died (p = 0.001). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for >11 points of SGS were 67, 100, 98, 100, and 98%, respectively.
CONCLUSIONS: This scoring system may help the clinicians to decide which patient to refer to a tertiary step hospital which may also decrease the cost and improve the functionality of healthcare staff.

Entities:  

Mesh:

Year:  2012        PMID: 22898483

Source DB:  PubMed          Journal:  J Vector Borne Dis        ISSN: 0972-9062            Impact factor:   1.688


  8 in total

1.  Is the brain spared in Crimean-Congo haemorrhagic fever? An MR-SWI study to reveal CNS involvement.

Authors:  Bilge Öztoprak; İbrahim Öztoprak; Aynur Engin
Journal:  Eur Radiol       Date:  2018-03-12       Impact factor: 5.315

2.  Which scoring system is effective in predicting mortality in patients with Crimean Congo hemorrhagic fever? A validation study.

Authors:  Mehmet Bakir; Caner Öksüz; Faruk Karakeçili; Nurcan Baykam; Şener Barut; Seyit Ali Büyüktuna; Zülal Özkurt; Murteza Öz; Orçun Barkay; Özlem Akdoğan; Nazif Elaldi; Murşit Hasbek; Aynur Engin
Journal:  Pathog Glob Health       Date:  2021-12-06       Impact factor: 3.735

3.  Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF).

Authors:  M Bakır; M G Gözel; I Köksal; Z Aşık; Ö Günal; H Yılmaz; A But; G Yılmaz; A Engin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-12       Impact factor: 3.267

Review 4.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

5.  Direct healthcare costs for patients hospitalized with Crimean-Congo haemorrhagic fever can be predicted by a clinical illness severity scoring system.

Authors:  Ilkay Bozkurt; Mustafa Sunbul; Hava Yilmaz; Saban Esen; Hakan Leblebicioglu; Nicholas J Beeching
Journal:  Pathog Glob Health       Date:  2016-02-25       Impact factor: 2.894

6.  Association Between Severity Grading Score And Acute Phase Reactants In Patients With Crimean Congo Hemorrhagic Fever.

Authors:  Ilkay Bozkurt; Saban Esen
Journal:  Pathog Glob Health       Date:  2021-01-23       Impact factor: 2.894

7.  Assessment of Inhibitors of Pathogenic Crimean-Congo Hemorrhagic Fever Virus Strains Using Virus-Like Particles.

Authors:  Marko Zivcec; Maureen G Metcalfe; César G Albariño; Lisa W Guerrero; Scott D Pegan; Christina F Spiropoulou; Éric Bergeron
Journal:  PLoS Negl Trop Dis       Date:  2015-12-01

8.  Multi-omics insights into host-viral response and pathogenesis in Crimean-Congo hemorrhagic fever viruses for novel therapeutic target.

Authors:  Ujjwal Neogi; Nazif Elaldi; Sofia Appelberg; Anoop Ambikan; Emma Kennedy; Stuart Dowall; Binnur K Bagci; Soham Gupta; Jimmy E Rodriguez; Sara Svensson-Akusjärvi; Vanessa Monteil; Akos Vegvari; Rui Benfeitas; Akhil Banerjea; Friedemann Weber; Roger Hewson; Ali Mirazimi
Journal:  Elife       Date:  2022-04-19       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.